Streetbeat News

Stock Prices

META

The Wall Street Journal's test revealed that Instagram's algorithm recommends inappropriate content, including sexualized videos, which led to a response from Meta Platforms, Inc (NASDAQ:META) and a decision by Bumble to halt advertisements on Meta's platforms. Despite Meta's response emphasizing their efforts to address the issue, the findings raise concerns about Instagram's content recommendation system. META shares were slightly up at the time of publication.

Portfolio Pulse from Anusuya Lahiri

November 27, 2023 | 4:15 pm

SHOP

Shopify Inc (NYSE:SHOP) shares rose after reporting a 22% year-on-year increase in Black Friday sales, reaching $4.1 billion. RBC Capital Markets and Oppenheimer maintained Outperform ratings with a price target of $80, while Needham held a Hold rating. Analysts attribute the growth to new merchant wins, e-commerce growth, and market share gains. The sales performance suggests a strong fourth quarter, with clothing, personal care, and jewelry as top categories.

Portfolio Pulse from Priya Nigam

November 27, 2023 | 4:11 pm

ROKU

Cannonball Research analyst Vasily Karasyov has upgraded Roku (NASDAQ:ROKU) from Neutral to Buy and set a new price target of $116.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 4:08 pm

LILM

Lilium N.V. (NASDAQ:LILM) shares surged after the company announced receiving the European Union Aviation Safety Agency (EASA) Design Organization Approval, which acknowledges Lilium's capability to design and develop safe and compliant electric vertical take-off and landing (eVTOL) aircraft. This approval positions Lilium as a leader in the eVTOL market, being the only manufacturer with both EASA and FAA certification bases for a powered lift eVTOL aircraft. The company is also seeking FAA type-certificate validation under the EU-U.S. Bilateral Aviation Safety Agreement.

Portfolio Pulse from Adam Eckert

November 27, 2023 | 4:08 pm

LLY

NVO

Novo Nordisk A/S (NYSE:NVO) is in discussions to introduce flexible pricing for its weight loss drug Wegovy, aiming to allow healthcare systems to adopt the medication with payments spread over time. Despite competition from Eli Lilly's (NYSE:LLY) upcoming weight-loss drug Zepbound, which is expected to be priced 20% lower, Novo Nordisk plans to maintain Wegovy's pricing but is open to risk-based contracts that could lead to long-term savings for healthcare providers. The company is also set to launch Wegovy in Japan, entering the Asian market amidst supply and demand challenges. NVO shares saw a slight decline of 1.15% recently.

Portfolio Pulse from Vandana Singh

November 27, 2023 | 4:04 pm

KHC

Kraft Heinz Co (NASDAQ:KHC) has announced a new share repurchase program authorized by its Board of Directors, allowing for the buyback of up to $3 billion in shares until December 26, 2026. The company plans to use excess cash for the buybacks after accounting for capital expenditures. CEO Miguel Patricio expressed confidence in the company's strategy and considered its shares to be an attractive investment. The repurchase program is flexible, with no obligation to buy a specific number of shares and can be adjusted or halted at any time. As of September 30, 2023, Kraft Heinz had $1.05 billion in cash and equivalents. Following the news, KHC shares saw a modest increase of 0.49% to $35.11.

Portfolio Pulse from Shivani Kumaresan

November 27, 2023 | 4:01 pm

AZN

AstraZeneca (NASDAQ:AZN) is evaluated against its competitors in the Pharmaceuticals industry. The analysis includes financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. AstraZeneca's P/E, P/B, and P/S ratios are below the industry average, suggesting potential undervaluation. However, its ROE, EBITDA, gross profit, and revenue growth are also below the industry average, indicating possible inefficiencies and lower profitability. The company's lower debt-to-equity ratio compared to its top 4 peers suggests a stronger financial position.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 4:00 pm

AVGO

Broadcom (NASDAQ:AVGO) is analyzed against competitors in the Semiconductors & Semiconductor Equipment industry. With a P/E ratio lower than the industry average, Broadcom may be undervalued based on growth potential. However, its high P/B and P/S ratios suggest possible overvaluation based on book value and sales. The company's ROE is above the industry average, indicating profitability and growth potential, but its EBITDA and gross profit are below the industry average, suggesting lower operational efficiency. Broadcom's revenue growth exceeds the industry average, showing strong sales expansion. The company's higher debt-to-equity ratio compared to top peers indicates higher financial risk.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 4:00 pm

OHI

Over the past 3 months, 8 Wall Street analysts have published opinions on Omega Healthcare Investors (NYSE:OHI), with an average price target of $34.38, representing an implied upside from the current price of $32.065. The consensus among these analysts is leaning towards a neutral stance, with 5 indifferent ratings, 2 bullish, and 1 somewhat bullish. The current average price target reflects a 4.82% increase from the previous target of $32.80.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 4:00 pm

ANSS

Ansys (NASDAQ:ANSS) is analyzed against its software industry peers, revealing it has a lower P/E, P/B, and higher P/S ratios compared to the industry average. Ansys's ROE, EBITDA, gross profit, and revenue growth are below its peers, indicating potential inefficiencies and weaker profitability. The company's lower debt-to-equity ratio suggests a stronger financial position with less reliance on debt financing.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 4:00 pm